ResMed Inc. reported robust financial results for the quarter ended December 31, 2024, with a 10% increase in net revenue and a 65% jump in net income, driven by strong demand across its Sleep and Breathing Health and Residential Care Software segments.
- 10% year-over-year net revenue growth to $1.28 billion
- 65% increase in net income to $344.6 million for Q2 2024
- Gross margin improved to 58.6%, up from 55.6% in prior year
- Continued investment in R&D at 6.3% of net revenues
- Strong liquidity position with $521.9 million cash and $1.5 billion credit facility available
Strong Revenue and Earnings Growth
ResMed Inc., a global leader in medical devices and cloud-based software for respiratory care, delivered a strong financial performance in the second quarter of fiscal 2024, ending December 31, 2024. The company reported net revenue of $1.28 billion, marking a 10% increase compared to the same period last year. This growth was broad-based, with both its Sleep and Breathing Health segment and Residential Care Software business contributing to the uplift.
Net income surged 65% to $344.6 million, reflecting improved operational efficiencies and favorable product mix. Diluted earnings per share rose to $2.34, up from $1.42 in the prior year quarter. The gross margin expanded to 58.6%, a notable improvement from 55.6% in the prior year, driven by manufacturing efficiencies, component cost improvements, and the absence of prior year non-recurring field safety notification expenses.
Segment Performance and Geographic Expansion
The Sleep and Breathing Health segment, which includes therapy-based devices and masks, generated $1.13 billion in revenue, an 11% increase year-over-year. Growth was fueled by increased demand and unit sales across major markets, including the U.S., Canada, Latin America, Europe, and Asia. The Residential Care Software segment also posted solid growth, with revenues rising 8% to $156.5 million, supported by expansion in the Home Medical Equipment and MEDIFOX DAN verticals.
Geographically, the U.S., Canada, and Latin America region saw a 12% increase in Sleep and Breathing Health revenues, while combined Europe, Asia, and other markets grew by 8% on a constant currency basis. This balanced global growth underscores ResMed’s expanding footprint and the rising awareness of sleep-disordered breathing and respiratory conditions worldwide.
Investment in Innovation and Operational Efficiency
ResMed continues to prioritize innovation, investing $81.4 million in research and development during the quarter, representing 6.3% of net revenues. The company highlighted its latest device, the AirSense 11, which features enhanced digital capabilities, including a touchscreen interface and over-the-air updates, reflecting ResMed’s commitment to advancing patient care through technology.
Operationally, the company benefited from manufacturing efficiencies and cost improvements, which contributed to margin expansion. Notably, amortization of acquired intangible assets declined as certain assets became fully amortized, further supporting profitability.
Liquidity and Capital Management
ResMed maintains a strong liquidity position, ending the quarter with $521.9 million in cash and cash equivalents and full availability under its $1.5 billion revolving credit facility. The company’s disciplined capital allocation included $125 million in share repurchases during the first half of fiscal 2024 and continued dividend payments, with a declared dividend of $0.53 per share payable in March 2025.
Cash flow from operations was robust at $634.2 million for the six months ended December 31, 2024, up from $559.1 million in the prior year period, reflecting higher net income partially offset by increased inventory investments.
Outlook and Strategic Positioning
ResMed’s management reaffirmed its strategic focus on accelerating growth through dedicated leadership in product development, revenue generation, and marketing. The company’s dual-segment model, combining medical devices with cloud-based software solutions, positions it well to capitalize on the ongoing shift toward home-based care and digital health management.
While the company faces typical industry risks, including supply chain challenges and foreign currency fluctuations, its strong financial foundation and innovation pipeline provide a solid platform for sustained growth.
Bottom Line?
ResMed’s Q2 results highlight a company gaining momentum through innovation and operational discipline, setting the stage for continued growth in a dynamic healthcare landscape.
Questions in the middle?
- How will ResMed’s investments in digital health platforms impact long-term revenue growth?
- What are the potential risks from ongoing patent litigations and regulatory changes?
- How might foreign currency volatility affect future earnings and margins?